Key result
Iloprost requires ~3-5 times higher concentrations to inhibit platelet shape change and early recruitment versus aggregation.
Why the study?
The relative sensitivities of ADP-induced platelet activation steps and prostaglandin-mediated inhibition by iloprost were not fully characterized.
Population
Platelet-rich plasma from 9 healthy human donors
Comparison
Iloprost inhibition of platelet shape change, early recruitment, and aggregation
Design
Preclinical in vitro study
Authors
Loading...
Standard assays may overestimate iloprost potency on early platelet activation; leaves open optimal in vivo dosing and human translation.
Iloprost differentially inhibits platelet activation steps, requiring higher concentrations to inhibit shape change and early recruitment compared to macro-aggregation.
Pedvis et al. (1988) studied Healthy (n=9). Iloprost (ZK 36374) was evaluated on Inhibition of rates of turbidometrically-measured aggregation (TA), early platelet recruitment (PA), and shape change (SC). Iloprost required 3-5 times higher concentrations to inhibit platelet shape change and early recruitment compared to the concentration needed to inhibit turbidometrically-measured aggregation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: